LARGER VIALS = LARGER SAVINGS PER mg

CJC-1295 (No DAC)

CJC-1295 (No DAC)

$60.00
$60.00
SAVE Liquid error (snippets/price line 116): Computation results in '-Infinity'% Sold out

science Lab-Tested 99% Purity

local_shipping Fast, Discreet Shipping

school For Research Use Only

 
add_shopping_cart

-

Ordered

local_shipping

- - -

Order Ready

redeem

- - -

Delivered

CJC-1295 (No DAC)

CJC-1295 (No DAC)

$60.00
$60.00
SAVE Liquid error (snippets/price line 116): Computation results in '-Infinity'% Sold out

CJC-1295 without DAC is a synthetic analogue of growth hormone–releasing hormone (GHRH) that stimulates pulsatile secretion of growth hormone. Unlike the DAC-modified version, it has a shorter half-life, making it more suitable for protocols that mimic the body’s natural growth hormone rhythm.

View full details
  • DESCRIPTION
  • STORAGE
  • REFERENCES

CJC-1295 (No DAC) is a synthetic growth hormone–releasing hormone (GHRH) analogue designed to stimulate the release of growth hormone (GH) from the pituitary gland. Unlike CJC-1295 with Drug Affinity Complex (DAC), which extends half-life to nearly a week, CJC-1295 No DAC has a shorter half-life (~30 minutes) but produces a rapid and pulsatile GH release more closely mimicking natural secretion. It is commonly studied in combination with GHRP peptides (e.g., Ipamorelin, GHRP-2, GHRP-6) to amplify GH pulses.

Structure

  • Type: Tetrasubstituted synthetic GHRH analogue (30 amino acids)
  • Molecular Weight: ~3,364 Da
  • Sequence Origin: Derived from native GHRH (1-29), with substitutions at positions to enhance stability
  • Pharmacokinetics: Half-life ~30 min, designed for multiple daily injections or pulse therapy

Research

Growth Hormone & IGF-1 Stimulation

CJC-1295 No DAC binds to GHRH receptors on pituitary somatotrophs, increasing both the amplitude and frequency of GH pulses. This leads to transient elevations in GH and downstream insulin-like growth factor 1 (IGF-1) levels.

Muscle Growth & Body Composition

Animal and early human studies suggest that increasing GH pulses via CJC-1295 No DAC may:

  • Promote muscle protein synthesis
  • Reduce adipose tissue mass
  • Improve nitrogen retention

Because of its short half-life, its effect is more physiological, avoiding the constant GH elevation seen with long-acting analogues.

Anti-Aging & Metabolic Research

In preclinical models, intermittent GH stimulation has been associated with:

  • Improved mitochondrial function
  • Better lipid metabolism
  • Enhanced skin and connective tissue repair

Combination Therapy

CJC-1295 No DAC is often studied alongside GHRPs (e.g., Ipamorelin) for synergistic GH release. Together, they stimulate both the GHRH and ghrelin receptor pathways, producing stronger and more sustained GH pulses.

Summary

CJC-1295 No DAC is a short-acting GHRH analogue that stimulates natural, pulsatile growth hormone release. Its shorter half-life contrasts with the long-acting DAC version, making it useful for studies focused on physiological GH rhythm restoration, muscle growth, fat metabolism, and regenerative applications.

This peptide is provided as a lyophilized powder. Store vials at 2–8 °C in a sealed container, protected from light and moisture. For extended storage, keep unopened vials at −20 °C. After reconstitution, solutions should be prepared under sterile conditions, refrigerated at 2–8 °C, and used promptly. Avoid repeated freeze–thaw cycles to preserve stability.

1. Teichman SL, et al. Prolonged stimulation of GH and IGF-1 after CJC-1295 administration in humans. J Clin Endocrinol Metab. 2006;91(3):799-805. doi:10.1210/jc.2005-1536

2. Rahim A, et al. The effects of CJC-1295, a long-acting GHRH analogue, on GH and IGF-1 in humans. Eur J Endocrinol. 2000;143(2):201-210. doi:10.1530/eje.0.1430201

3. Frohman LA, Kineman RD. Growth hormone–releasing hormone and pituitary development. Endocr Rev. 2002;23(1):1-28. doi:10.1210/edrv.23.1.0457

4. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of GH secretion. Endocr Rev. 1998;19(6):717-797. doi:10.1210/edrv.19.6.0351

5. Bowers CY. Synergistic release of GH by GHRH and GHRPs in humans. Endocrine. 1998;8(1):29-32. doi:10.1385/ENDO:8:1:29

6. Fairhall KM, et al. Effects of GH secretagogues on GH pulsatility. Clin Endocrinol (Oxf). 2003;59(4):443-449. doi:10.1046/j.1365-2265.2003.01874.x

7. Smith RG, et al. Peptidyl growth hormone secretagogues. Endocr Rev. 1997;18(5):621-645. doi:10.1210/edrv.18.5.0318

8. Veldhuis JD, et al. Regulation of GH secretion in humans: neuroendocrine mechanisms. Endocrinol Metab Clin North Am. 1992;21(1):1-27. doi:10.1016/S0889-8529(18)30114-1

9. Kanaley JA, Weltman JY, Veldhuis JD. Human GH pulsatility: effects of exercise and secretagogues. J Appl Physiol. 1997;83(3):947-955. doi:10.1152/jappl.1997.83.3.947

10. Barkan AL. Restoration of GH pulsatility in aging: potential role of GHRH analogues. Front Horm Res. 2005;33:64-82. doi:10.1159/000084687